Latest news with #AmbroiseFayolle
Yahoo
27-05-2025
- Business
- Yahoo
TreeFrog Therapeutics Secures €30 Million From European Investment Bank (EIB) Marking a Significant Milestone in the Company's Journey to Accelerate the Field of Cell Therapy
€30 million financing with mix of dilutive and venture debt financing Funds to advance Parkinson's disease cell therapy program to the clinic and further develop their internal pipeline of cell therapies Deal benefits from guarantee under European Commission's Invest EU program BORDEAUX, France, May 27, 2025--(BUSINESS WIRE)--TreeFrog Therapeutics, a French biotech specializing in cell therapy has secured a €30 million financing from the European Investment Bank (EIB). The financing will support the advancement of their lead cell therapy program in Parkinson's Disease to the clinic. Funds will also be used to reinforce their internal pipeline in other disease areas with large unmet needs. Regenerative medicine holds immense potential to revolutionize healthcare to treat or cure some of the world's unmet needs in diseases of the major organs, such as the heart, lungs, pancreas and brain. Parkinson's disease is the second most common neurodegenerative disorder and the fastest growing with more than 10 million people worldwide suffering from the disease. Prevalence doubled in the last 25 years and is expected to double again before 2050. Current solutions treat symptoms only. The cell therapy in development at TreeFrog has the potential to be a best-in-class treatment due to its unique 3D format microtissues, developed from induced pluripotent cells (iPSC). The program is on track to be ready for a first-in-human trial in 2027. The €30 million financing will be available in 3 tranches of €10 million each, with TreeFrog benefiting from a new vehicle from the EIB, mixing dilutive financing, hence no principal repayment required for the initial two tranches and venture debt for the last tranche. The initial €10 million will be withdrawn during the second quarter of 2025. EIB's investment aligns with the InvestEU objective of fostering research, development and innovation. Ambroise Fayolle, vice-president of the EIB, said: "Regenerative medicine is a field that has growing importance as life expectancy rises and some diseases are still untreated. This EIB is keen to support young, dynamic European and French companies that focus on research, development and product innovation. Support from InvestEU is testimony of a wider European interest in TreeFrog's business model and new solutions for the health sector". Jaime Arango, Chief Finance Officer, TreeFrog Therapeutics, said: "We are delighted to receive this support from EIB which bolsters our cash visibility trajectory and enables us to bring our Parkinson's cell therapy to the clinic, while also reinforcing our internal pipeline of cell therapies in other disease areas." TreeFrog's success in attracting investment and partners to date is based on their proprietary technology platform, C-Stem™. This platform addresses some of the major challenges by producing high quality cells, efficiently, at commercial scale. C-Stem combines microfluidics and stem cell biology to mimic the natural environment for cells. The cells are encapsulated in alginate capsules seeded with iPSCs. These capsules protect the cells, allowing them to do what they do naturally – self-organise and grow. The protected cells are nurtured and nourished, expand exponentially and can be turned into any type of cell in large-scale bioreactors without damage and stress. This results in 3D microtissues that have unique benefits in terms of quality and functionality and integrate well after transplant. Background information About EIB The European Investment Bank (EIB), whose shareholders are the Member States of the European Union (EU), is the EU's long-term financing institution. Across eight major priorities, we support investments in climate action and the environment, digital transition and technological innovation, security and defense, cohesion, agriculture and the bioeconomy, social infrastructure, capital markets union, and a stronger Europe in a more peaceful and prosperous world. In 2024, the EIB Group, which also includes the European Investment Fund (EIF), signed nearly €89 billion in new financing in support of more than 900 projects in Europe and worldwide. In France, the EIB Group signed over a hundred operations in 2024 for a total amount of €12.6 billion. Nearly 60% of the EIB Group's annual financing supports projects contributing to climate change mitigation and adaptation, as well as the creation of a healthier environment. About TreeFrog Therapeutics TreeFrog Therapeutics is a French-based regenerative medicine biotech set to unlock access to cell therapies for millions of patients. TreeFrog is unique in its approach to cell therapy development, bringing together biophysicists, cell biologists and bioproduction engineers to address the challenges of the industry - producing and differentiating cells of quality at unprecedented scale, cost-effectively. To succeed in their mission of Cell Therapy for all, TreeFrog operates a business model that includes its own therapeutic programs and partnerships with leading biotech and industry players. Since 2021, the company has raised $82 million to advance a pipeline of stem cell-based therapies in regenerative medicine. View source version on Contacts Press contactsEIB Andrea Morawski, mobile: +352 691 284 349Website: - Press Office: press@ TreeFrog Therapeutics Rachel MooneyChief Communications Tel: +33 674063461
Associated Press
27-05-2025
- Business
- Associated Press
TreeFrog Therapeutics Secures €30 Million From European Investment Bank (EIB) Marking a Significant Milestone in the Company's Journey to Accelerate the Field of Cell Therapy
BORDEAUX, France--(BUSINESS WIRE)--May 27, 2025-- TreeFrog Therapeutics, a French biotech specializing in cell therapy has secured a €30 million financing from the European Investment Bank (EIB). The financing will support the advancement of their lead cell therapy program in Parkinson's Disease to the clinic. Funds will also be used to reinforce their internal pipeline in other disease areas with large unmet needs. This press release features multimedia. View the full release here: Vice-President Ambroise Fayolle, EIB and Frederic Desdouits, CEO TreeFrog Therapeutics sign financing of €30million to accelerate cell therapy programs. Regenerative medicine holds immense potential to revolutionize healthcare to treat or cure some of the world's unmet needs in diseases of the major organs, such as the heart, lungs, pancreas and brain. Parkinson's disease is the second most common neurodegenerative disorder and the fastest growing with more than 10 million people worldwide suffering from the disease. Prevalence doubled in the last 25 years and is expected to double again before 2050. Current solutions treat symptoms only. The cell therapy in development at TreeFrog has the potential to be a best-in-class treatment due to its unique 3D format microtissues, developed from induced pluripotent cells (iPSC). The program is on track to be ready for a first-in-human trial in 2027. The €30 million financing will be available in 3 tranches of €10 million each, with TreeFrog benefiting from a new vehicle from the EIB, mixing dilutive financing, hence no principal repayment required for the initial two tranches and venture debt for the last tranche. The initial €10 million will be withdrawn during the second quarter of 2025. EIB's investment aligns with the InvestEU objective of fostering research, development and innovation. Ambroise Fayolle, vice-president of the EIB, said: 'Regenerative medicine is a field that has growing importance as life expectancy rises and some diseases are still untreated. This EIB is keen to support young, dynamic European and French companies that focus on research, development and product innovation. Support from InvestEU is testimony of a wider European interest in TreeFrog's business model and new solutions for the health sector'. Jaime Arango, Chief Finance Officer, TreeFrog Therapeutics, said: 'We are delighted to receive this support from EIB which bolsters our cash visibility trajectory and enables us to bring our Parkinson's cell therapy to the clinic, while also reinforcing our internal pipeline of cell therapies in other disease areas.' TreeFrog's success in attracting investment and partners to date is based on their proprietary technology platform, C-Stem™. This platform addresses some of the major challenges by producing high quality cells, efficiently, at commercial scale. C-Stem combines microfluidics and stem cell biology to mimic the natural environment for cells. The cells are encapsulated in alginate capsules seeded with iPSCs. These capsules protect the cells, allowing them to do what they do naturally – self-organise and grow. The protected cells are nurtured and nourished, expand exponentially and can be turned into any type of cell in large-scale bioreactors without damage and stress. This results in 3D microtissues that have unique benefits in terms of quality and functionality and integrate well after transplant. Background information About EIB The European Investment Bank (EIB), whose shareholders are the Member States of the European Union (EU), is the EU's long-term financing institution. Across eight major priorities, we support investments in climate action and the environment, digital transition and technological innovation, security and defense, cohesion, agriculture and the bioeconomy, social infrastructure, capital markets union, and a stronger Europe in a more peaceful and prosperous world. In 2024, the EIB Group, which also includes the European Investment Fund (EIF), signed nearly €89 billion in new financing in support of more than 900 projects in Europe and worldwide. In France, the EIB Group signed over a hundred operations in 2024 for a total amount of €12.6 billion. Nearly 60% of the EIB Group's annual financing supports projects contributing to climate change mitigation and adaptation, as well as the creation of a healthier environment. About TreeFrog Therapeutics TreeFrog Therapeutics is a French-based regenerative medicine biotech set to unlock access to cell therapies for millions of patients. TreeFrog is unique in its approach to cell therapy development, bringing together biophysicists, cell biologists and bioproduction engineers to address the challenges of the industry - producing and differentiating cells of quality at unprecedented scale, cost-effectively. To succeed in their mission of Cell Therapy for all, TreeFrog operates a business model that includes its own therapeutic programs and partnerships with leading biotech and industry players. Since 2021, the company has raised $82 million to advance a pipeline of stem cell-based therapies in regenerative medicine. View source version on CONTACT: Press contacts EIB Andrea Morawski,[email protected], mobile: +352 691 284 349 Website: Press Office:[email protected] TreeFrog Therapeutics Rachel Mooney Chief Communications Officer [email protected] Tel: +33 674063461 KEYWORD: EUROPE UNITED STATES NORTH AMERICA FRANCE INDUSTRY KEYWORD: OTHER HEALTH RESEARCH BANKING GENERAL HEALTH PROFESSIONAL SERVICES PUBLIC RELATIONS/INVESTOR RELATIONS SCIENCE BIOTECHNOLOGY COMMUNICATIONS FINANCE OTHER SCIENCE HEALTH SOURCE: TreeFrog Therapeutics Copyright Business Wire 2025. PUB: 05/27/2025 07:15 AM/DISC: 05/27/2025 07:14 AM
Yahoo
27-05-2025
- Business
- Yahoo
TreeFrog Therapeutics Secures €30 Million From European Investment Bank (EIB) Marking a Significant Milestone in the Company's Journey to Accelerate the Field of Cell Therapy
€30 million financing with mix of dilutive and venture debt financing Funds to advance Parkinson's disease cell therapy program to the clinic and further develop their internal pipeline of cell therapies Deal benefits from guarantee under European Commission's Invest EU program BORDEAUX, France, May 27, 2025--(BUSINESS WIRE)--TreeFrog Therapeutics, a French biotech specializing in cell therapy has secured a €30 million financing from the European Investment Bank (EIB). The financing will support the advancement of their lead cell therapy program in Parkinson's Disease to the clinic. Funds will also be used to reinforce their internal pipeline in other disease areas with large unmet needs. Regenerative medicine holds immense potential to revolutionize healthcare to treat or cure some of the world's unmet needs in diseases of the major organs, such as the heart, lungs, pancreas and brain. Parkinson's disease is the second most common neurodegenerative disorder and the fastest growing with more than 10 million people worldwide suffering from the disease. Prevalence doubled in the last 25 years and is expected to double again before 2050. Current solutions treat symptoms only. The cell therapy in development at TreeFrog has the potential to be a best-in-class treatment due to its unique 3D format microtissues, developed from induced pluripotent cells (iPSC). The program is on track to be ready for a first-in-human trial in 2027. The €30 million financing will be available in 3 tranches of €10 million each, with TreeFrog benefiting from a new vehicle from the EIB, mixing dilutive financing, hence no principal repayment required for the initial two tranches and venture debt for the last tranche. The initial €10 million will be withdrawn during the second quarter of 2025. EIB's investment aligns with the InvestEU objective of fostering research, development and innovation. Ambroise Fayolle, vice-president of the EIB, said: "Regenerative medicine is a field that has growing importance as life expectancy rises and some diseases are still untreated. This EIB is keen to support young, dynamic European and French companies that focus on research, development and product innovation. Support from InvestEU is testimony of a wider European interest in TreeFrog's business model and new solutions for the health sector". Jaime Arango, Chief Finance Officer, TreeFrog Therapeutics, said: "We are delighted to receive this support from EIB which bolsters our cash visibility trajectory and enables us to bring our Parkinson's cell therapy to the clinic, while also reinforcing our internal pipeline of cell therapies in other disease areas." TreeFrog's success in attracting investment and partners to date is based on their proprietary technology platform, C-Stem™. This platform addresses some of the major challenges by producing high quality cells, efficiently, at commercial scale. C-Stem combines microfluidics and stem cell biology to mimic the natural environment for cells. The cells are encapsulated in alginate capsules seeded with iPSCs. These capsules protect the cells, allowing them to do what they do naturally – self-organise and grow. The protected cells are nurtured and nourished, expand exponentially and can be turned into any type of cell in large-scale bioreactors without damage and stress. This results in 3D microtissues that have unique benefits in terms of quality and functionality and integrate well after transplant. Background information About EIB The European Investment Bank (EIB), whose shareholders are the Member States of the European Union (EU), is the EU's long-term financing institution. Across eight major priorities, we support investments in climate action and the environment, digital transition and technological innovation, security and defense, cohesion, agriculture and the bioeconomy, social infrastructure, capital markets union, and a stronger Europe in a more peaceful and prosperous world. In 2024, the EIB Group, which also includes the European Investment Fund (EIF), signed nearly €89 billion in new financing in support of more than 900 projects in Europe and worldwide. In France, the EIB Group signed over a hundred operations in 2024 for a total amount of €12.6 billion. Nearly 60% of the EIB Group's annual financing supports projects contributing to climate change mitigation and adaptation, as well as the creation of a healthier environment. About TreeFrog Therapeutics TreeFrog Therapeutics is a French-based regenerative medicine biotech set to unlock access to cell therapies for millions of patients. TreeFrog is unique in its approach to cell therapy development, bringing together biophysicists, cell biologists and bioproduction engineers to address the challenges of the industry - producing and differentiating cells of quality at unprecedented scale, cost-effectively. To succeed in their mission of Cell Therapy for all, TreeFrog operates a business model that includes its own therapeutic programs and partnerships with leading biotech and industry players. Since 2021, the company has raised $82 million to advance a pipeline of stem cell-based therapies in regenerative medicine. View source version on Contacts Press contactsEIB Andrea Morawski, mobile: +352 691 284 349Website: - Press Office: press@ TreeFrog Therapeutics Rachel MooneyChief Communications Tel: +33 674063461 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Zawya
04-03-2025
- Business
- Zawya
EBID, EIB announce $105mln partnership to boost climate action in ECOWAS region
THE ECOWAS Bank for Investment and Development (EBID) and the European Investment Bank (EIB), with support from the European Union (EU), have announced a €100 million financial partnership to promote climate action and environmental sustainability projects across the ECOWAS region. The agreement, signed on Friday, February 28, 2025, marks the EIB's first collaboration with EBID, underscoring both institutions' commitment to sustainable development in West Africa. The €100 million credit line is part of a larger €150 million financing envelope and will fund projects that address climate change, promote environmental sustainability, and boost economic growth. The initiative is expected to fill the financing gap in key sectors, such as renewable energy, sustainable agriculture, and water treatment, contributing to poverty reduction and improved livelihoods in the ECOWAS region. 'This partnership demonstrates EBID's commitment to supporting regional member countries' access to sustainable sources of finance,' said Dr. Mory Soumahoro, EBID Vice President of Risk and Control. The facility will particularly support small and medium-sized photovoltaic solar projects, clean energy solutions, and environmental conservation initiatives that align with the region's climate mitigation strategies. The initiative aligns with the strategic priorities of the ECOWAS region, including the ECOWAS Vision 2050, which focuses on environmental protection, private sector development, and regional integration. The project also supports the ECOWAS Regional Climate Strategy and the 2022-2030 Action Plan, aimed at building climate resilience across West Africa. The partnership contributes directly to several Sustainable Development Goals (SDGs), including: Affordable and Clean Energy (SDG 7); Clean Water and Sanitation (SDG 6); Sustainable Agriculture (SDG 2); Health and Quality Education (SDG 3 and SDG 4). 'This operation will help bridge the financial gap in this region while contributing to poverty reduction and improving daily lives,' said Ambroise Fayolle, EIB Vice-President. 'Through EIB Global, we aim to support the EU's Global Gateway Initiative and key sectors such as renewable energy, digital economy, agriculture, and transport.' The Global Gateway strategy is the EU's model for building stronger, more resilient connections with partner regions. The EIB is a key player in this initiative, aiming to support €100 billion in investments by 2027 — approximately one-third of the strategy's total target. Highlighting the partnership's significance, Jozef Síkela, European Commissioner for International Partnerships, said: 'More than half a billion people in Africa still lack access to electricity. Our long-standing goal is to change that. This partnership is a clear demonstration of our commitment to supporting sustainable development and climate action in Africa. By mobilising €300 million for clean energy projects, we are empowering people in the ECOWAS region to build a greener and more prosperous future.' The EIB loan will be accompanied by a technical assistance program that provides training and capacity building for climate action-focused projects. The program is aligned with the EIB and EBID's broader initiatives supporting sustainable infrastructure, innovation, and environmental protection. The European Investment Bank (EIB) is the financing institution of the EU, supporting projects that contribute to the Union's key objectives. EIB Global, its specialist arm for international partnerships, aims to strengthen the impact of development finance by supporting the Global Gateway Initiative and working with local institutions to promote sustainable investments. The ECOWAS Bank for Investment and Development (EBID) is the financial arm of ECOWAS, dedicated to financing development projects that promote regional integration and economic development across West Africa. The partnership between EBID, EIB, and the EU represents a major step in addressing climate change and promoting sustainable development in the ECOWAS region. As projects under this facility take off, the collaboration is expected to not only bridge financing gaps but also improve livelihoods, create jobs, and support a greener, more resilient future for West Africa.
Zawya
27-02-2025
- Business
- Zawya
European Investment Bank (EIB) backs Africa Finance Corporation $750 Million Climate Resilient Infrastructure Fund
The European Investment Bank (EIB) has committed to join Africa Finance Corporation (AFC) ( in financing a $750 million Infrastructure Climate Resilient Fund (ICRF). This landmark initiative will accelerate climate adaptation and sustainable infrastructure across Africa. As part of this commitment, the EIB today confirmed it will invest $52.48 million in the Fund, which is managed by AFC Capital Partners (ACP), the asset management arm of AFC. ACP has already secured a $253 million commitment from the Green Climate Fund (GCF), marking GCF's largest-ever equity investment in Africa. In addition, the Nigeria Sovereign Investment Authority (NSIA) and two private African pension funds have also committed to the Fund, demonstrating robust institutional backing on the continent and internationally. The Infrastructure Climate Resilient Fund aims to accelerate climate adaptation in Africa by embedding resilience measures at every stage of infrastructure development—from design and construction to operation. Using blended finance to de-risk private investment, the Fund also integrates innovative tools such as climate risk parametric insurance to enhance protection against climate-related risks and losses. In addition, the Fund will provide technical assistance to enhance the capacity of countries seeking climate risk assessment and adaptation, aligning with the European Union's Global Gateway initiative and the UN Sustainable Development Goals. The EIB formally signed the agreement at the Finance in Common Summit (FICS) in Cape Town today, demonstrating the close collaboration between the EIB, AFC, and other strategic partners. "The EIB is committed to supporting private sector investment in climate-resilient infrastructure, especially in regions most vulnerable to climate change,' EIB Vice-President Ambroise Fayolle stated at the ceremony today. 'This partnership with the Africa Finance Corporation and the launch of ACP's Infrastructure Climate Resilient Fund are a significant step towards accelerating Africa's green and digital transition and ensuring a sustainable future for all. The EIB's investment is not just about the initial capital injection; it is also intended to have a multiplier effect by attracting more investors, reducing risk, showcasing successful projects, and promoting best practices in climate finance." ACP's fund aims to demonstrate that Africa can pursue a climate-resilient and sustainable development path by addressing market failures, mitigating environmental risks, strengthening logistics, trade, and industrialization, and accelerating the continent's digital and energy transition. "This Fund is crucial for bridging the funding gap for climate adaptation in Africa,' Samaila Zubairu, AFC's President&CEO, said at the launch event today. 'By focusing on climate-resilient infrastructure, we are not only securing our economic future but also creating opportunities for sustainable growth, and supporting job creation across the continent. We are glad to partner with the EIB and other investors who are committed to increasing the impact of climate finance.' Developing Climate-Resilient Infrastructure The ICRF focuses on Africa, the world's most climate-vulnerable continent, by investing in infrastructure that can withstand the impacts of climate change while reducing carbon emissions. The Fund prioritizes resilient, low-carbon solutions across transport and logistics, clean energy, digital infrastructure, and industrial development, ensuring sustainable growth. ACP's investment strategy evaluates climate risk across both physical and transition dimensions, including emissions and climate governance. The Fund is committed to ensuring that infrastructure assets are designed, built, and operated to withstand and adapt to evolving climate conditions. To achieve this, ACP will conduct rigorous climate risk screenings and assessments for every investment, establishing a new benchmark for selecting and implementing the most effective adaptation solutions. The Fund leverages a powerful partnership between three major institutions—EIB, AFC, and GCF—uniting their expertise, capital, and commitment to climate resilience. Aligned with the EIB's Climate Bank Roadmap, ACP will draw on the proven track records and deep technical expertise of both EIB and AFC in infrastructure investment, creating a compelling platform to attract additional investors. Through this strategic collaboration, the $750 million fund is poised to unlock up to $3.7 billion in financing, accelerating the deployment of climate-resilient infrastructure across Africa. The GCF will play a critical role by providing technical assistance for due diligence and climate resilience monitoring while also covering the first-loss tranches on new investments, effectively de-risking projects and attracting private capital. Once operational, the Fund aims to invest in a diversified portfolio of 10 to 12 projects across Africa. It will also assist countries and entities in capacity building and deployment of climate risk assessment and adaptation solutions. Further Information Leveraging Partnerships The Fund is built on a powerful partnership between three major institutions: the European Investment Bank (EIB), Africa Finance Corporation (AFC), and the Green Climate Fund (GCF). Through its asset management arm, AFC Capital Partners (ACP), AFC is collaborating with the EIB to deploy the Fund, leveraging both institutions' proven track records and technical expertise in infrastructure investment to attract additional investors. The partnership is further strengthened by the GCF's critical role in providing first-loss protection and technical assistance, ensuring a robust framework for scaling climate-resilient infrastructure across Africa. Mobilizing Climate Finance The EIB's $52.48 million commitment is a strategic step toward the Fund's $750 million target, aimed at catalysing additional investments from both private and public sector partners into climate-resilient infrastructure. This commitment is expected to help mobilize approximately $3.7 billion in total financing, driving tangible, on-the-ground impact across Africa. Focusing on EIB's core priorities agreed by ECOFIN The EIB investment will support the climate bank ambition to accelerate international action on adaptation and resilience. With an expected climate action and environmental sustainability contribution of about 80%, the operation will contribute to EIB's objectives to dedicate (i) 50% of its financing toward climate action and environmental sustainability and (ii) 15% of its financing toward to climate adaptation by 2025. The Fund supports three of the five EU Global Gateway thematic priorities: i) climate and energy, ii) transport and iii) digital. Addressing Market Failures The EIB investment in ACP's Infrastructure Climate Resilient Fund is intended to address the scarcity of equity capital for greenfield infrastructure projects, and to help overcome other market failures such as the lack of incentives for green energy solutions or market failures related to transport accessibility and digital connectivity. The Fund also aims to improve the efficiency of logistics and trade corridors and contribute to the digital and energy transition. Supporting the Green and Digital Transition By investing in clean energy and digital infrastructure, the Fund aims to support the broader green and digital transition in Africa and contribute to diversification and security of energy supply, as well as improved access to digital connectivity. Enhancing Capacity for Climate Risk Management ACP's Infrastructure Climate Resilient Fund will provide technical assistance to build capacity for climate risk assessment and adaptation, with a focus on integrating climate risk considerations into project design and construction. Creating Jobs and Economic Opportunities Projects backed by ACP's Infrastructure Climate Resilient Fund will contribute to job creation, economic growth, and improved quality of life in the target regions. These projects are expected to generate significant temporary employment during construction as well as permanent jobs during operation. Key projects in the ICRF pipeline, such as the Lobito Corridor, underscore AFC's pivotal role in driving transformational and climate-resilient infrastructure investments across Africa. As the lead developer of the project, AFC is spearheading efforts to enhance regional connectivity and economic integration through the corridor, which is set to become a critical trade and logistics route linking Angola, the Democratic Republic of Congo (DRC), and Zambia. The Lobito Corridor is expected to unlock vast economic opportunities by facilitating efficient transportation of critical minerals, agricultural goods, and other commodities, reducing dependency on other congested export routes and fostering industrial development along the wider corridor. Alongside partners including the European Union, the United States Government, the African Development Bank and the governments of Angola, the Democratic Republic of Congo and Zambia, AFC is working to ensure the corridor is developed with climate resilience in mind, integrating sustainable infrastructure solutions that can withstand environmental challenges while promoting long-term economic growth. Beyond Lobito, the ICRF pipeline includes other strategic projects across transport, clean energy, and digital infrastructure, all designed to attract institutional investment and address Africa's pressing infrastructure gap. Through these initiatives, ACP continues to highlight its commitment to mobilizing capital for projects that deliver both financial returns and lasting developmental impact. The investments backed by the Fund will actively promote the adoption of Environmental, Social, and Governance (ESG) best practices, including gender equality, protection, and anti-discrimination policies. De-risking Investments The Fund's structure, with support from the EIB and other institutions like the Green Climate Fund (GCF), aims to de-risk climate investments. The GCF is providing grant funding to help with due diligence and monitoring of climate resilience, which can make the investments more attractive to other investors. Additionally, the Fund will integrate innovative climate risk insurance to complement traditional indemnity programs. Aligning with Global and Regional Objectives The EIB investment aligns with EU strategies, the African Union's Agenda 2063, and the UN Sustainable Development Goals, and aims to support the implementation of Nationally Determined Contributions. Distributed by APO Group on behalf of Africa Finance Corporation (AFC). Press contacts: Richard Willis tel.: +352 43 79 82155 Mobile: +352 621 55 57 58 Website: Press Office: press@ Yewande Thorpe tel +234 1 279 9654 Website: Press office: communications@ Social Media: Twitter: Facebook: Instagram: YouTube: RSS Feed: LinkedIn: Follow EIB Global on: Twitter: LinkedIn: About EIB Global EIB Global ( is the EIB Group's specialised arm dedicated to increasing the impact of international partnerships and development finance. EIB Global is designed to foster strong, focused partnership within Team Europe ( alongside fellow development finance institutions, and civil society. EIB Global brings the Group closer to local people, companies and institutions through our offices across the world ( About AFC: AFC was established in 2007 to be the catalyst for pragmatic infrastructure and industrial investments across Africa. AFC's approach combines specialist industry expertise with a focus on financial and technical advisory, project structuring, project development, and risk capital to address Africa's infrastructure development needs and drive sustainable economic growth. Seventeen years on, AFC has developed a track record as the partner of choice in Africa for investing and delivering on instrumental, high-quality infrastructure assets that provide essential services in the core infrastructure sectors of power, natural resources, heavy industry, transport, and telecommunications. AFC has 45 member countries and has invested over US$15 billion in 36 African countries since its inception.
